CLINICAL TRIALS AND OBSERVATIONS Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma
نویسندگان
چکیده
1Division of Hematology, Mayo Clinic, Rochester, MN; 2Sarah Cannon Research Institute, Nashville, TN; 3Department of Medical Oncology Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA; 4Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI; 5Bone Marrow/Hematology Clinics, University of Wisconsin Comprehensive Cancer Center, Madison, WI; 6Sinai Hospital of Baltimore, Baltimore, MD; 7Division of Hematology and Oncology, Mayo Clinic Arizona, Scottsdale, AZ; 8Department of Medicine, Feist-Weiller Cancer Center, Louisiana State University Health Sciences Center, Shreveport, LA; 9Rocky Mountain Cancer Centers, Denver, CO; 10Clinical Research, University of California San Francisco, San Francisco, CA; and 11Millennium Pharmaceuticals Inc, Cambridge, MA
منابع مشابه
CLINICAL TRIALS AND OBSERVATIONS A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis
In this phase 1/2 study, we explored the feasibility and activity of an oral regimen of lenalidomide with low-dose dexamethasone and low-dose oral cyclophosphamide (RdC) in patients with primary systemic light chain amyloidosis. RdC was given for up to 12 cycles in prespecified cohorts at escalated doses: 13 patients were treated in phase 1 and 24 in phase 2; 65% were previously untreated, and ...
متن کاملRegular Article CLINICAL TRIALS AND OBSERVATIONS A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma Paul G. Richardson, Wanling Xie, Sundar Jagannath, Andrzej Jakubowiak, Sagar Lonial, Noopur S. Raje, Melissa Alsina, Irene M. Ghobrial, Robert L. Schlossman, Nikhil C. Munshi, Amitabha Mazumder, David H. Vesole, Jonathan L. Kaufman, Kathleen Colson, Mary McKenney, Laura E. Lu...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial
Andrzej J. Jakubowiak,1 Kent A. Griffith,1 Donna E. Reece,2 Craig C. Hofmeister,3 Sagar Lonial,4 Todd M. Zimmerman,4 Erica L. Campagnaro,5 Robert L. Schlossman,6 Jacob P. Laubach,6 Noopur S. Raje,7 Tara Anderson,1 Melissa A. Mietzel,1 Colleen K. Harvey,1 Sandra M. Wear,8 Jennifer C. Barrickman,9 Craig L. Tendler,10 Dixie-Lee Esseltine,11 Susan L. Kelley,8 Mark S. Kaminski,1 Kenneth C. Anderson,...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study
1Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine and Cancer Institute, Pittsburgh, PA; 2Myeloma Program, Karmanos Cancer Institute, Detroit, MI; 3University of Pittsburgh Medical Center Cancer Centers, Pittsburgh, PA; 4Biostatistics Facility, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA; and 5College of ...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
We report the results of a phase 2 trial using lenalidomide plus dexamethasone (Rev/ Dex) as initial therapy for myeloma. Thirtyfour patients were enrolled. Lenalidomide was given orally 25 mg daily on days 1 to 21 of a 28-day cycle. Dexamethasone was given orally 40 mg daily on days 1 to 4, 9 to 12, and 17 to 20 of each cycle. Objective response was defined as a decrease in serum monoclonal pr...
متن کامل